Health

Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Prospects & Upcoming Trends and Opportunities Upto 2020

Press Release

The global hospital acquired pneumonia drug market has been analyzed by Transparency Market Research (TMR) to give a complete description of the market and its growth in the coming years. The hospital acquired pneumonia drug market is fragmented due to the presence of a large number of vendors. Few vendors are likely to adopt pricing strategies that would increase the competition in the market. Furthermore, companies are likely to adopt strategies such as high investments to adopt newer technologies, research and development activities, and mergers and acquisitions to strengthen their position in the market. Companies leading the market include GlaxoSmithKline, Achaogen, Inc., Cubist Pharmaceutical, Aridis Pharmaceutical, Bayer Healthcare, AstraZeneca PLC, Basilea Pharmaceutica Ltd., Merck & Co., Meiji Seika Pharma Co., Ltd., and Valneva SE.

As per TMR, the global market for hospital acquired pneumonia drug is projected to reach US$ 3.8 bn by the end of 2020. North America is expected to lead the market during the forecast period. This is for the reason that the region witnesses a high incidence of pneumonia and hospital-acquired infections. The presence of large number of vendors has also made the North America market grow distinctively.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1881

Immunocompromised Patients Are Prone to Acquire Pneumonia from hospitals

Patients who have undergone a surgery, are on enteral feeding, or are immunocompromised are more vulnerable to acquiring hospital acquired pneumonia. The hospital acquired pneumonia is also prevalent among the newborns, as they might suffer from respiratory syncytial virus (RSV) which has been identified as one of the major reason for nosocomial pneumonia.

The increasing incidence of hospital acquired pneumonia has pushed the government to take effective and strict measures that can address the root cause of these types of infections. Many programs have been implemented to minimize the cases related to hospital acquired pneumonia, but that will certainly minimize the need for hospital acquired pneumonia drugs in the overall market. One restraint may hinder the hospital acquired pneumonia drug market to grow during the forecast period.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1881

Subsidized Standards Of Living in Developing Economies Increasing the Demand for Hospital Acquired Pneumonia Drugs

The demand for hospital acquired pneumonia drug has increased mainly due to the unhealthy environment in hospitals and inadequate healthcare infrastructure in developing economies. The healthcare conditions in the growing economies are very low as per the international standards and lack in proper hygiene are leading to increasing healthcare associated diseases. The factors that create an unhealthy environment are often caused due to inadequate financial resources, poor infrastructure, and over-crowded hospitals that increase the chances of communicable diseases. In addition, inappropriate use of sanitary drugs and inadequate sanitary condition have increased the chances of development of MDR microorganism, the organism responsible for the rise of hospital acquired pneumonia.

The information presented in this review is based on a TMR report, titled “Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market (Late Stage Candidates – (Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix); Early Stage Candidates (Phase II, Phase I and Preclinical Trials – AR-101 or KBPA101, GSK 2189242A, BAL30072, MEDI4893, AR 301 or KBSA301, ME1100, V114, AR-104 or KBPA104, AR-201 or KBRV201, AR-401 or KBAB401) Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020”.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact Us

Transparency Market Research

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: [email protected]

Website: https://www.transparencymarketresearch.com